Cost-effectiveness of fracture prevention in established osteoporosis.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Scandinavian Journal of Rheumatology. Supplement

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.3109/03009749609103742PMID 8966488
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Predicting various fragility fractures in women by forearm bone densitometry: A follow-up study

  1993cited by this paper
• Mortality and morbidity after hip fractures.

  1993cited by this paper
• Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.

  1993cited by this paper
• Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.

  1992cited by this paper
• Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

  1992cited by this paper
• Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component.

  1991cited by this paper
• Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group.

  1991cited by this paper
• The costs of treating hypertension in Sweden. An empirical investigation in primary health care.

  1991cited by this paper
• Costs of hip fracture. Rehabilitation of 180 patients in primary health care.

  1991cited by this paper
• Postmenopausal estrogens in prevention of osteoporosis. Benefit virtually without risk if cardiovascular effects are considered.

  1986cited by this paper

• Cost-effectiveness of romosozumab for the treatment of postmenopausal women at very high risk of fracture in Canada

  2022cites this paper
• Osteoporose: Entstehung, Prophylaxe und Therapie

  2019cites this paper
• A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.

  2017cites this paper
• Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

  2015cites this paper
• Cost-effectiveness analysis of hip fracture prevention with vitamin D supplementation: a Markov micro-simulation model applied to the French population over 65 years old without previous hip fracture

  2014cites this paper
• Secondary prevention of osteoporotic fractures: room for improvement

  2014cites this paper
• Projecte Rossó: Junts contra l’Osteoporosi

  2014cites this paper
• Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm

  2013cites this paper
• Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

  2013cites this paper
• Recommendations for the Health Economics Analysis to be Performed with a Drug to be Registered in Prevention or Treatment of Osteoporosis

  2013cites this paper
• Cost-effectiveness of universal serologic screening to prevent nontraumatic hip and vertebral fractures in patients with celiac disease.

  2013cites this paper
• Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain

  2013cites this paper
• Osteoporosis in the European Union: medical management, epidemiology and economic burden

  2013cites this paper
• Economic Evaluation of Norethisterone Acetate/Ethinylestradiol (FemHRT®) for Women with Menopausal Symptoms

  2012cites this paper
• Cost Effectiveness of Alendronate (Fosamax®) for the Treatment of Osteoporosis and Prevention of Fractures

  2012cites this paper
• Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden

  2012cites this paper
• Hip Fracture Prevention

  2012cites this paper
• Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective

  2011influential citation
• Current and future economic burden of osteoporosis in New Zealand

  2011cites this paper
• Principles of health economics and application to rheumatic disorders

  2011cites this paper
• Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

  2011cites this paper
• The societal burden of poor persistence to treatment of osteoporosis in Sweden.

  2011cites this paper
• FRAX and its applications in health economics--cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example.

  2010cites this paper
• Cost effectiveness of teriparatide and PTH(1-84) in the treatment of postmenopausal osteoporosis

  2010influential citation
• Original article Cost effectiveness of teriparatide and PTH(1-84) inthetreatmentofpostmenopausalosteoporosis

  2010cites this paper
• The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

  2010cites this paper
• Vitamin K to prevent fractures in older women: systematic review and economic evaluation.

  2009cites this paper
• Cost-effectiveness of hormone replacement therapy for menopausal symptoms in the UK

  2009cites this paper
• Management of osteoporosis in central and eastern Europe (CEE): conclusions of the “2nd Summit on Osteoporosis—CEE”, 21–22 November 2008, Warsaw, Poland

  2009cites this paper
• Cost-Effectiveness of Hormone Therapy in the United States

  2009cites this paper
• Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.

  2008cites this paper
• Health economics of osteoporosis.

  2008influential citation
• Per- und subtrochantäre Femurfrakturen

  2008cites this paper
• The cost-effectiveness of alendronate in the management of osteoporosis.

  2008cites this paper
• Utility Values Associated with Osteoporotic Fracture: A Systematic Review of the Literature

  2008cites this paper
• Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden

  2008cites this paper
• Incorporating adherence into health economic modelling of osteoporosis

  2008cites this paper
• Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial

  2007cites this paper
• Incidence and costs of hip fractures compared to acute myocardial infarction in the Italian population: a 4-year survey

  2007cites this paper
• Aromatase inhibitors--socioeconomical issues.

  2007cites this paper
• The societal burden of osteoporosis in Sweden.

  2007cites this paper
• Cost-effectiveness model for Sweden Background document

  2007cites this paper
• Cost-effectiveness model for Sweden

  2007cites this paper
• Community-Based Youth Tobacco Control Interventions

  2006cites this paper
• Aromatase inhibitors as adjuvant treatment of breast cancer.

  2006cites this paper
• Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer.

  2006cites this paper
• Cost-effectiveness Strategies to Treat Osteoporosis in Elderly Women

  2006cites this paper
• At what hip fracture risk is it cost-effective to treat?

  2006cites this paper
• The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective

  2006cites this paper
• An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting

  2006cites this paper
• Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model

  2006cites this paper
• Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

  2006cites this paper
• Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures

  2005cites this paper
• Management of the patient with suspected temporal arteritis a decision-analytic approach.

  2005cites this paper
• The clinical effectiveness and cost effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in post menopausal women

  2005cites this paper
• Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature

  2005cites this paper
• Intervention thresholds for osteoporosis in the UK.

  2005cites this paper
• Cost-utility analyses in orthopaedic surgery.

  2005cites this paper
• Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries

  2005cites this paper
• Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.

  2004cites this paper
• A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms

  2004cites this paper
• Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden

  2004influential citation
• Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

  2004cites this paper
• Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial

  2004cites this paper
• Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

  2004cites this paper
• The risk and burden of vertebral fractures in Sweden

  2004cites this paper
• Models for Assessing the Cost-Effectiveness of the Treatment and Prevention of Osteoporosis

  2002cites this paper
• Direct Medical Costs Attributable to Osteoporotic Fractures

  2002cites this paper
• Femoral neck fractures in the elderly: Functional outcome and quality of life according to EuroQol

  2002cites this paper
• Treatment of established osteoporosis: a systematic review and cost-utility analysis.

  2002cites this paper
• The Burden of Osteoporosis in California, 1998

  2002cites this paper
• COST AND EFFECTIVENESS OF HIP PROTECTORS AMONG THE ELDERLY

  2002cites this paper
• THE HEALTH ECONOMICS OF CALCIUM AND VITAMIN D3 FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURES IN SWEDEN

  2002cites this paper
• [Cost-effectiveness of alendronate treatment of osteoporosis in Denmark. An economic evaluation based on the Fracture Intervention Trial].

  2002influential citation
• Costs and quality of life associated with osteoporosis related fractures: Results from a Swedish survey

  2002cites this paper
• Economic Implications of Hip Fracture: Health Service Use, Institutional Care and Cost in Canada

  2001cites this paper
• A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden

  2001cites this paper
• Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry.

  2001cites this paper
• Equity and the economic evaluation of healthcare.

  2001cites this paper
• New aspects in health economic studies of prevention and treatment of osteoporosis

  2001cites this paper
• The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds

  2001cites this paper
• Challenges for Model-Based Economic Evaluations of Postmenopausal Osteoporosis Interventions

  2001cites this paper
• Cost-Effectiveness of Preventing Hip Fracture in the General Female Population

  2001cites this paper
• Cost‐effectiveness research in osteoporosis

  2000cites this paper
• Determinants of Bone Loss from the Femoral Neck in Women of Different Ages

  2000cites this paper
• A computer model to analyse the cost-effectiveness of hormone replacement therapy - a revised version

  2000cites this paper
• Health burden of hip and other fractures in Australia beyond 2000: Projections based on the Geelong Osteoporosis Study

  1999cites this paper
• A critical structured review of economic evaluations of interventions for the prevention and treatment of osteoporosis

  1999cites this paper
• Incidence and long-term cost of steroid-related side effects after renal transplantation.

  1999cites this paper
• Raising the quality of cost-utility analyses: lessons learnt and still to learn.

  1999cites this paper
• A COMPUTER MODEL TO ANALYZE THE COST-EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY

  1999cites this paper
• Die Kosten hüftgelenksnaher Frakturen in Deutschland: Eine prospektive Untersuchung

  1999cites this paper
• Osteoporosis and bone densitometry: does the emperor have clothes?

  1998cites this paper
• Quality of Life in the Economic Evaluation of Osteoporosis Prevention and Treatment

  1997cites this paper
• The Osteoporosis Revolution

  1997cites this paper